ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANA"

  • Abstract Number: 1535 • ACR Convergence 2021

    Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination

    Rebecca Blank1, Rebecca Haberman2, Rochelle Castillo2, marie Samanovic3, Parvathy Vasudevanpillai Girija4, Paula Rackoff1, Gary Solomon5, Natalie Azar6, Pamela Rosenthal7, Peter Izmirly4, Jonathan Samuels8, Brian Golden9, Soumya Reddy7, Steven B. Abramson4, Mark Mulligan3 and Jose Scher4, 1New York University, New York, NY, 2NYU Langone Health, New York, NY, 3NYU Grossman School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY, 5NYU Langone School of Medicine, Hartsdale, NY, 6NYU Langone, New York, NY, 7NYU School of Medicine, New York, NY, 8NYU Langone, Rye Brook, NY, 9NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY

    Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
  • Abstract Number: 0003 • ACR Convergence 2021

    Clinically Identifiable Autoreactivity Is Common in Severe SARS-CoV-2 Infection

    Richard Ramonell1, Matthew Woodruff2, Mark Rudolph3, F. Eun-Hyung Lee1 and Iñaki Sanz4, 1Emory University, Atlanta, GA, 2Emory University, Decatur, GA, 3Exagen Inc., Vista, CA, 4Emory University School of Medicine, Atlanta, GA

    Background/Purpose: A massive expanson of plasmablasts or antibody secreting cells (ASC) have been shown in severe patients with SARS-CoV-2 infection and in patients with autoimmune…
  • Abstract Number: 0347 • ACR Convergence 2021

    Longitudinal ANA Titers in SLE and ANA+ Controls

    Emily Littlejohn1, Lingxuan Kong2, Kelly Speth2, Lu Wang2 and Emily Somers2, 1Cleveland Clinic, Cleveland, OH, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
  • Abstract Number: 1517 • ACR Convergence 2021

    Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade

    Sophia Weinmann1, Amanda Eudy2 and David Pisetsky1, 1Duke University Medical Center, Durham, NC, 2Duke University, Durham, NC

    Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
  • Abstract Number: 265 • 2019 ACR/ARP Annual Meeting

    Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline

    Pamela Anjara 1, David Liew2, Victor Yang 3, Christopher McMaster 2 and Russell Buchanan 3, 1Austin Hospital, Melbourne, Victoria, Australia, 2Austin Health, Melbourne, Victoria, Australia, 3Austin Health, Heidelberg, Victoria, Australia

    Background/Purpose: In October 2017, the Australian Rheumatology Association widely promoted a list of five recommendations on low-value practices to general clinicians and patients as part…
  • Abstract Number: 306 • 2019 ACR/ARP Annual Meeting

    Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders

    Jihad Ben Gabr1 and Andras Perl 1, 1SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: The American College of Rheumatology (ACR) established case definitions of 19 specific neuropsychiatric syndromes seen in patients with systemic lupus erythematosus (SLE) (1).  Therefore,…
  • Abstract Number: 308 • 2019 ACR/ARP Annual Meeting

    Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays

    Konrad Dziamski1 and Andras Perl 1, 1SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Indirect immunofluorescence (IF) is the recommended initial test for detection of antinuclear antibodies (ANA) by the American College of Rheumatology (Ann Rheum. Dis 69:1420-2),…
  • Abstract Number: 790 • 2019 ACR/ARP Annual Meeting

    Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?

    Ovgu Kul Cinar1, Charlene Foley 2, Ali Al-Hussain 3, Kimberly Gilmour 4, Matthew Buckland 4 and Muthana Al-Obaidi 5, 1Great Ormond Street Hospital, Lonodn, United Kingdom, 2Great Ormond Street Hospital, London, Ireland, 3Great Ormond Street Hospital, London, United Kingdom, 4Great Ormond Street Hospital NHS Trust, Camelia Botnar Laboratories, London, United Kingdom, 5Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Antinuclear antibodies (ANA) are autoantibodies that recognise cellular antigens found predominantly in the cell nucleus. They are associated with numerous autoimmune diseases such as…
  • Abstract Number: 791 • 2019 ACR/ARP Annual Meeting

    Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis

    May Choi1, Emily Mirizio 2, Fernanda Quinteros 3, Katherine Buhler 4, Marvin Fritzler 1 and Kathryn Torok 5, 1Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2University of Pittsburgh, Pittsburgh, 3University of Calgary, Calgary, 4University of Calgary, Calgary, Canada, 5UPMC Children's Hospital of Pittsburgh, Pittsburgh

    Background/Purpose: It has become increasingly recognized that extra-cutaneous manifestations, such as musculoskeletal and neurologic involvement, are common in pediatric patients with localized scleroderma (LS). We…
  • Abstract Number: 110 • 2018 ACR/ARHP Annual Meeting

    Single-Cell RNA-Seq Analysis of ANA+ Healthy and SLE Patients Show Variations in Activated Stress Response and Regulatory Pathways

    Miles C. Smith1, Samantha Slight-Webb1, Susan R. Macwana1, Judith A. James2,3 and Joel M. Guthridge1, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Medicine & Pathology, Univ. of Oklahoma, Okla, OK

    Background/Purpose: One hallmark of the autoimmune disease Systemic lupus erythematosus (SLE) is the presence of antinuclear antibodies (ANAs). While the specificities and levels can indicate…
  • Abstract Number: 554 • 2018 ACR/ARHP Annual Meeting

    Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?

    Yuki Ishikawa1, Motomu Hashimoto2, Hiromu Ito3, Masao Tanaka2, Naoichiro Yukawa4, Takao Fujii5, Wataru Yamamoto6, Tsuneyo Mimori7 and Chikashi Terao8,9,10, 1One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Wakayama University, Wakayama, Japan, 5Dept of Rheum/Clinical Immun, Wakayama Medical University, Wakayama, Japan, 6Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, 7Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 8Center for Investigative Medical Sciences, RIKEN, Yokohama, Japan, 9Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, 10Department of Applied Genetics, The School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

    Background/Purpose: It has been well known that anti-TNF-α treatment for RA patients is associated with ANA development. We previously reported that ANA development along with…
  • Abstract Number: 758 • 2018 ACR/ARHP Annual Meeting

    Cutaneous Lupus Erythematosus Patients with a Negative ANA Meeting Acr and/or SLICC Criteria for Systemic Lupus Erythematosus

    Meera Tarazi1, Carolyn Kushner2, Rebecca Gaffney2 and Victoria P. Werth3, 1Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 2Dermatology, University of Pennsylvania, Philadelphia, PA, 3Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Systemic lupus erythematosus (SLE) is a disorder that is heterogeneous and can be difficult to diagnose. One hallmark of the disease is the presence…
  • Abstract Number: 1188 • 2018 ACR/ARHP Annual Meeting

    Are Residents Choosing Wisely? Analysis of Adherence to Recommendations of Ordering Anti-Nuclear Antibody Testing in an Internal Medicine Residency Primary Care Clinic

    Aparna Das, Rajarajan Panneerselvan, Annum Faisal, Jubran Rind and Rima Shah, Internal medicine, Michigan state university, grand rapids, MI

    Background/Purpose: A positive anti-nuclear antibody (ANA) is considered very useful for the diagnosis of SLE and systemic sclerosis, and somewhat useful for the diagnosis of…
  • Abstract Number: 1683 • 2018 ACR/ARHP Annual Meeting

    Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer

    Mark Wener1 and Mark H. Wener2, 1Division of Rheumatology, Department of Laboratory Medicine, University of Washington, Seattle, WA, 2Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Titers of HEp-2 ANAs vary between laboratories, with many contributing factors. We sought to systematically determine the contribution of different ANA kit manufacturers to…
  • Abstract Number: 2107 • 2018 ACR/ARHP Annual Meeting

    Lupus-Prone SLE1.2.3. Mice Exhibit Loss of Thymus-Derived CD4+CD25+Helios+ Tregs

    Nick Huang1, Zhi-Wei Lai1, Gourav Choudhary2, Thomas Winans3, Ryan Kelly4, Katalin Banki5, Laurence Morel6 and Andras Perl1, 1Medicine, SUNY Upstate Medical University, Syracuse, NY, 2Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, 3SUNY Upstate Medical University, Syracuse, NY, 4SUNY, Syracuse, NY, 5Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, 6Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL

    Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease that is characterized by the production of autoantibodies against nuclear antigens (ANA) and phospholipids…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology